Invention Grant
![Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide](/docs/US/2021-07-13/US11059803B2/abs.jpg.600x600.jpg)
- Patent Title: Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
-
Application No.: US16628618Application Date: 2018-07-04
-
Publication No.: US11059803B2Publication Date: 2021-07-13
- Inventor: Bibia Heidmann , Markus Von Raumer
- Applicant: IDORSIA PHARMACEUTICALS LTD
- Applicant Address: CH Allschwil
- Assignee: IDORSIA PHARMACEUTICALS LTD
- Current Assignee: IDORSIA PHARMACEUTICALS LTD
- Current Assignee Address: CH Allschwil
- Agency: Hoxie & Associates LLC
- Priority: WOPCT/EP2017/066806 20170705
- International Application: PCT/EP2018/068087 WO 20180704
- International Announcement: WO2019/008034 WO 20190110
- Main IPC: C07D401/06
- IPC: C07D401/06
![Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide](/abs-image/US/2021/07/13/US11059803B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved.
Public/Granted literature
Information query
